||Recombinant Human BMP8A (Accession # AAP74559) Ala264-His402 was produced in Chinese Hamster Ovary cell line, CHO-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in HCl.
||Measured by its ability to inhibit the cell growth of DU145 human prostate carcinoma cells. Miyazaki, H. et al. (2004) Oncogene 23:9326.The ED50 for this effect is typically 0.2-1 µg/mL.
||Recombinant Human BMP8A has a calculated MW of 15.7 kDa (monomer). In SDS-PAGE migrates as 19 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).